生产企业：Norroy Bioscience Co., Ltd.
68Ga-NYM096 is a potential radiopharmaceutical PET imaging agent targeting carbonic anhydrase IX (CAIX), developed by Norroy Bioscience for PET imaging of clear cell renal cell carcinoma (ccRCC). It is the first China-originated innovative radiopharmaceutical to receive FDA Breakthrough Therapy Designation, and has also been granted FDA Fast Track designation.
68Ga-NYM096 is a potential radiopharmaceutical PET imaging agent targeting carbonic anhydrase IX (CAIX), developed by Norroy Bioscience for PET imaging of clear cell renal cell carcinoma (ccRCC). It is the first China-originated innovative radiopharmaceutical to receive FDA Breakthrough Therapy Designation, and has also been granted FDA Fast Track designation.
Targets carbonic anhydrase IX (CAIX) for PET imaging of clear cell renal cell carcinoma (ccRCC); a non-invasive PET imaging agent that binds the CAIX target to characterize indeterminate renal masses and differentiate ccRCC from non-ccRCC lesions.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
